VRDN251017C00030000 Option on Viridian Therapeutics

An 'Out of The Money' option on Viridian has a strike price that Viridian Stock has yet to reach, meaning the option has no intrinsic value. 'Out of The Money' options are usually less costly than 'In The Money' options, making them more desirable to traders with smaller amounts of capital. Some of the uses for Viridian Therapeutics' 'Out of The Money' options include buying the options if you expect a big move in Viridian Therapeutics' stock. Since 'Out of The Money' options have a lower up-front cost (i.e., no intrinsic value) than 'In The Money' options, buying it is a reasonable choice.

Viridian Therapeutics' Option Greeks for the contract ending on 2025-10-17 at a strike price of 30.0 measures the various factors that affect its cost and calculated using a theoretical options pricing model. It helps investors make more informed decisions about whether to trade this option contract or when to trade it. In addition to Viridian Therapeutics' option greeks, its implied volatility helps estimate the risk of Viridian Therapeutics stock implied by the prices of the options on Viridian Therapeutics' stock.

Put options written on Viridian Therapeutics grant holders of the option the right to sell a specified amount of Viridian Therapeutics at a specified price within a specified time frame. The put buyer has a limited loss and, while not fully unlimited gains, as the price of Viridian Stock cannot fall below zero, the put buyer does gain as the price drops. So, purchasing a put option on Viridian Therapeutics is like buying insurance aginst Viridian Therapeutics' downside shift.

By selling Viridian Therapeutics' put option, the investors signal their bearish sentiment. A short position in a put option written on Viridian Therapeutics will generally make money when the underlying price is above the strike price. Therefore Viridian Therapeutics' put payoff at expiration depends on where the Viridian Stock price is relative to the put option strike price. The breakeven price of 30.98 is the critical point that divides the payoff function into two parts. Below the breakeven price, the payoff is dropping and negative (the seller makes a loss). Above the breakeven price, the payoff line is upward sloping as the option payoff increases in proportion to Viridian Therapeutics' price. Finally, at the strike price of 30.0, the payoff chart is constant and positive.

Viridian Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Viridian. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Viridian. It also shows strike prices and maturity days for a Viridian Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.